The markets traded mixed during the midday with the Dow edging up a point to 16,169. Nasdaq lost 13 points to 4056.
On the upside
Alimera Sciences (Nasdaq: ALIM) and pSivida (Nasdaq: PSDV) entered labeling discussions with the Food and Drug Administration for their eye disease treatment Iluvien.
Oxygen Biotherapeutics (Nasdaq: OXBT) will begin enrolling patients in a Phase 3 clinical trial of its low cardiac output syndrome treatment levosimendan in the third quarter of 2014.
IAC/InterActive (Nasdaq: IACI) reorganized its corporate structure be eliminating the chief executive position and moving chief executive Greg Blatt to become chairman of the newly created Match Group.
On the downside
Winnebago Industries (NYSE: WGO) reported sharply higher first quarter earnings but revenue fell short of analyst expectations.
Rosetta Resources (Nasdaq: ROSE) announced a $1.1 billion capital budget for 2014.
KB Home (NYSE: KBH) swung to a profit for the fourth quarter but the results missed expectations by a wide margin.
In the broad market, declining issues outpaced advancer by a margin of more than 5 to 3 on the NYSE and by more than 3 to 2 on Nasdaq. The broader S&P 500 slipped 2 points to 1807. Bitcoin soared $97.86 or 16.79% to $680.81.
